A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

Recruiting

Phase 1

Phase 2

BleximenibA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

Sponsor:

Janssen Research & Development, LLC

Code:

NCT04811560

Conditions

Acute Leukemias

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Bleximenib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-04-03.